Johnson & Johnson to Host Analyst Meeting to Discuss Three Late-Stage Pipeline Compounds Presented at American College of Rheumatology (ACR) Conference

Johnson & Johnson will sponsor an analyst meeting and webcast for financial analysts on Thursday, November 8, from 5:00-6:00 p.m. (Eastern Time) to coincide with the American College of Rheumatology’s annual meeting in Boston. The analyst meeting will be held in the Republic Ballroom at the Sheraton Boston Hotel located at 39 Dalton Street in Boston, approximately three miles from the Convention and Exhibition Center where the ACR meeting is taking place.

The Company will discuss data being presented at ACR on three compounds in its late-stage pharmaceutical pipeline: golimumab (CNTO 148), ustekinumab (CNTO 1275), and tapentadol.

Joanne Waldstreicher, M.D., Global Head, Drug Development, CNS/Internal Medicine Franchise, and Jay Siegel, M.D., Group President, Research & Development, Biotech, Immunology & Oncology Franchise, will host the meeting.

A webcast will be available through www.jnj.com. Please click on the webcast icon for further instructions.